AU2014229082C1 - Managing osteoporosis with HMW PEG - Google Patents

Managing osteoporosis with HMW PEG Download PDF

Info

Publication number
AU2014229082C1
AU2014229082C1 AU2014229082A AU2014229082A AU2014229082C1 AU 2014229082 C1 AU2014229082 C1 AU 2014229082C1 AU 2014229082 A AU2014229082 A AU 2014229082A AU 2014229082 A AU2014229082 A AU 2014229082A AU 2014229082 C1 AU2014229082 C1 AU 2014229082C1
Authority
AU
Australia
Prior art keywords
peg
bone
hmw
hmw peg
ovx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014229082A
Other languages
English (en)
Other versions
AU2014229082A1 (en
AU2014229082B2 (en
Inventor
Laura Rae MCCABE
Rifat Pamukcu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University
Midway Pharmaceuticals Inc
Original Assignee
Michigan State University
Midway Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University, Midway Pharmaceuticals Inc filed Critical Michigan State University
Publication of AU2014229082A1 publication Critical patent/AU2014229082A1/en
Application granted granted Critical
Publication of AU2014229082B2 publication Critical patent/AU2014229082B2/en
Priority to AU2018250501A priority Critical patent/AU2018250501B2/en
Publication of AU2014229082C1 publication Critical patent/AU2014229082C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014229082A 2013-03-15 2014-03-14 Managing osteoporosis with HMW PEG Active AU2014229082C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018250501A AU2018250501B2 (en) 2013-03-15 2018-10-19 Managing Osteoporosis With HMW PEG

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798481P 2013-03-15 2013-03-15
US61/798,481 2013-03-15
PCT/US2014/028832 WO2014144425A1 (en) 2013-03-15 2014-03-14 Managing osteoporosis with hmw peg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018250501A Division AU2018250501B2 (en) 2013-03-15 2018-10-19 Managing Osteoporosis With HMW PEG

Publications (3)

Publication Number Publication Date
AU2014229082A1 AU2014229082A1 (en) 2015-11-05
AU2014229082B2 AU2014229082B2 (en) 2018-07-19
AU2014229082C1 true AU2014229082C1 (en) 2019-01-17

Family

ID=51537706

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014229082A Active AU2014229082C1 (en) 2013-03-15 2014-03-14 Managing osteoporosis with HMW PEG
AU2018250501A Active AU2018250501B2 (en) 2013-03-15 2018-10-19 Managing Osteoporosis With HMW PEG

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018250501A Active AU2018250501B2 (en) 2013-03-15 2018-10-19 Managing Osteoporosis With HMW PEG

Country Status (11)

Country Link
US (2) US10045949B2 (enExample)
EP (1) EP2968159B1 (enExample)
JP (3) JP6275239B2 (enExample)
AU (2) AU2014229082C1 (enExample)
CY (1) CY1122568T1 (enExample)
DK (1) DK2968159T3 (enExample)
ES (1) ES2744828T3 (enExample)
HU (1) HUE045032T2 (enExample)
PL (1) PL2968159T3 (enExample)
PT (1) PT2968159T (enExample)
WO (1) WO2014144425A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419823B (zh) * 2020-04-30 2022-03-29 上海公谊药业有限公司 一种延胡索酸泰妙菌素肠溶微丸及其制备方法和用途
NL1044084B1 (nl) 2021-07-05 2023-01-11 Evers Agro B V Mestinjecteur

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198817A1 (en) * 2002-11-26 2006-09-07 Alverdy John C Materials and methods for preventing and treating microbe-mediated epithelial disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10338646A (ja) * 1996-08-26 1998-12-22 Takeda Chem Ind Ltd 骨形成促進医薬組成物
JPWO2004105825A1 (ja) * 2003-01-10 2006-07-20 多木化学株式会社 骨形成用生体材料、該材料を含む注入用製剤、及び該材料を調製するためのキット、並びにこれらを用いる骨形成方法
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US9675696B2 (en) * 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
US8153112B2 (en) 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
MX2011009988A (es) * 2009-03-23 2011-11-18 Univ Chicago Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones.
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060198817A1 (en) * 2002-11-26 2006-09-07 Alverdy John C Materials and methods for preventing and treating microbe-mediated epithelial disorders

Also Published As

Publication number Publication date
EP2968159A1 (en) 2016-01-20
EP2968159B1 (en) 2019-06-12
CY1122568T1 (el) 2021-01-27
JP2016513738A (ja) 2016-05-16
JP6275239B2 (ja) 2018-02-07
US20160000730A1 (en) 2016-01-07
AU2014229082A1 (en) 2015-11-05
AU2018250501A1 (en) 2018-11-15
HUE045032T2 (hu) 2019-12-30
JP2017082009A (ja) 2017-05-18
JP6619849B2 (ja) 2019-12-11
JP2018162328A (ja) 2018-10-18
ES2744828T3 (es) 2020-02-26
DK2968159T3 (da) 2019-08-12
US10045949B2 (en) 2018-08-14
AU2018250501B2 (en) 2020-06-25
PT2968159T (pt) 2019-10-01
AU2014229082B2 (en) 2018-07-19
US20190015353A1 (en) 2019-01-17
PL2968159T3 (pl) 2019-11-29
WO2014144425A1 (en) 2014-09-18
EP2968159A4 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
Meganck et al. Evaluation of a protocol to reduce the incidence of neonatal calf diarrhoea on dairy herds
Tatara et al. Effects of combined maternal administration with alpha-ketoglutarate (AKG) and β-hydroxy-β-methylbutyrate (HMB) on prenatal programming of skeletal properties in the offspring
Grange et al. Evaluation of splenectomy as a risk factor for gastric dilatation-volvulus
BR112012001938B1 (pt) mistura de pó seco e composição de gel fluidificável suave e viscoso em suspensão na água e kit para o tratamento de um grupo de aves
Lyons et al. Strongyloides westeri and Parascaris equorum: Observations in field studies in Thoroughbred foals on some farms in Central Kentucky, USA
AU2018250501B2 (en) Managing Osteoporosis With HMW PEG
Tomaszewska et al. Chronic dietary supplementation with kynurenic acid, a neuroactive metabolite of tryptophan, decreased body weight without negative influence on densitometry and mandibular bone biomechanical endurance in young rats
MXPA04004904A (es) Uso de glutamato, derivados o metabolitos de glutamato, analogos de glutamato o mezclas de los mismos para la preparacion de una composicion para el tratamiento de osteoporosis.
Díaz et al. Effect of feeding three lysine to energy diets on growth, body composition and age at puberty in replacement gilts
Fuchs et al. A comparison of the carcase characteristics of pigs immunized with a ‘gonadotrophin-releasing factor (GnRF)’vaccine against boar taint with physically castrated pigs
Hiob et al. Efficacy of an injectable toltrazuril–gleptoferron (Forceris®) to control coccidiosis (Cystoisospora suis) in comparison with iron supplemented piglets without anticoccidial treatment
Hooshmand et al. Dietary l-carnitine supplementation improves bone mineral density by suppressing bone turnover in aged ovariectomized rats
Molter et al. Use of deslorelin acetate implants to mitigate aggression in two adult male domestic turkeys (Meleagris gallopavo) and correlating plasma testosterone concentrations
Harvey et al. Effect of daily lithium chloride administration on bone mass and strength in growing broiler chickens
Dumas et al. Effect of creep and post-weaning feeding composition on piglets’ intestinal health and post-weaning growth according to their creep feed consumption status
Ridley et al. The efficacy of pyrantel pamoate against ascarids and hookworms in cats
Zeni et al. Differences in bone turnover and skeletal response to thyroid hormone treatment between estrogen-depleted and repleted rats
Yan The effects of dietary probiotic inclusion on skeletal health of poultry and its possible mechanisms
Dhakal et al. Uterine spaciousness during embryo and fetal development in multiparous sows improves birth weight and postnatal growth performance
Tymczyna et al. Interrelationships between morphometric, densitometric, and mechanical properties of mandible in 6-month-old male pigs
Stacenko et al. Usage of “Feed Back” as an ecologically safe and effective means for preventing rotoviral infection of piglets
Liesegang et al. The effect of carprofen on selected markers of bone metabolism in dogs with chronic osteoarthritis
Frobose Stimulating estrus and ovulation in lactating sows and consequences for pig growth
Taylor Aspects of nitrogen metabolism in ruminants in health and disease
Hatt et al. Differences in the rumen washing mechanism in sheep with concentration and size of abrasives

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 SEP 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 21 SEP 2018

FGA Letters patent sealed or granted (standard patent)